You are here

Study: Acute Myeloid Leukemia Is at Least 11 Different Diseases

Findings may improve future diagnosis and treatment

Scientists at the Wellcome Trust Sanger Institute in Cambridge, United Kingdom, and their international collaborators have shown that acute myeloid leukemia (AML) is not a single disorder, but at least 11 different diseases, and that genetic changes explain differences in survival among young AML patients. Published in the New England Journal of Medicine, the groundbreaking study on the genetics of AML could improve clinical trials and the way patients are diagnosed and treated in the future, according to the authors.

In the largest study of its kind, researchers studied 1,540 patients with AML who were enrolled in clinical trials. They analyzed more than 100 genes known to cause leukemia to identify common genetic themes behind the development of the disease.

The researchers found that the patients were divided into at least 11 major groups, each with different constellations of genetic changes and distinctive clinical features. Despite finding common themes, however, the study also showed that most patients had a unique combination of genetic changes driving their leukemia. This genetic complexity helps explain why AML shows such variability in survival rates among patients.

Full knowledge of the genetic make-up of a patient’s leukemia substantially improved the ability to predict whether that patient would be cured with current treatments. This information could be used to design new clinical trials to develop the best treatments for each AML subtype, with the ultimate aim of bringing more extensive genetic testing into routine clinical practice, according to the researchers.

AML is an aggressive blood cancer that affects people of all ages, often requiring months of intensive chemotherapy in a hospital. The disease develops in bone marrow cells.

Sources: Wellcome Trust Sanger Institute; June 9, 2016; and New England Journal of Medicine; June 9, 2016.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs